Amarel

Quick links to important sections

Amarel

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Amarel

Quick Facts

Property Description
Active ingredient Glimepiride
Form Oral tablet
Pharmacological class Sulfonylurea, Insulin secretagogue
Common use Improvement of glycemic control in Type 2 diabetes
Origin Synthetic small molecule

What Type of Medication is Amarel (Glimepiride)?

Amarel is the brand name for a prescription-only oral blood-glucose-lowering drug defined by its active ingredient, glimepiride.

The medication is a synthetic small molecule compound, prepared for oral intake as a tablet formulation, which establishes its route of administration. Amarel is generally recognized as a single-ingredient product, and glimepiride is classified within the sulfonylurea class of antidiabetic medications. This category confirms its primary role in addressing high blood sugar. Specifically, glimepiride is generally considered a second-generation sulfonylurea, a distinction that highlights its modern pharmacological profile compared to older agents.

Glimepiride: Purpose and Action as an Insulin Secretagogue

The primary function of Amarel is to serve as an insulin secretagogue, a pharmacological action focused on stimulating the pancreas to release more of its own stored insulin. This means the medicine is designed to help the body produce and mobilize the insulin necessary to process sugar.

This mechanism is fundamental to the drug’s general purpose: achieving improvement of glycemic control by actively reducing persistently high blood sugar levels or hyperglycemia in adults with Type 2 diabetes mellitus. Glimepiride promotes direct insulin secretion while also exhibiting favorable extrapancreatic effects, which include the enhancement of peripheral insulin sensitivity. This dual benefit of secretion and sensitization ensures a more efficient utilization of circulating glucose, confirming its essential role as a hypoglycemic agent in managing the condition.

What side effects are possible with Amarel?

Possible Side Effects and Safety Information

The most prominent and serious safety concern associated with Amarel (glimepiride) is hypoglycemia (low blood sugar), which can be severe, potentially leading to unconsciousness, convulsions, or lasting neurological impairment. Symptoms of low blood sugar may be different or less noticeable in elderly patients, those with autonomic neuropathy, or individuals taking beta-blockers.

In clinical trials, the most common non-hypoglycemia-related adverse reactions occurring at a rate of 5% or more and more frequently than placebo included headache, nausea, and dizziness.

Serious and Rare Adverse Reactions

Postmarketing surveillance has identified rare but serious adverse reactions, including severe hypersensitivity responses such as anaphylaxis, angioedema, and Stevens-Johnson Syndrome. If a serious hypersensitivity reaction is suspected, the medication must be discontinued immediately.

Blood and liver function changes have also been reported. Rare hematologic effects can include hemolytic anemia, particularly in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Cases of liver function impairment, including cholestasis and hepatitis, have also been documented.

Safety Considerations and Restrictions

Amarel is contraindicated in patients with known hypersensitivity to glimepiride, other sulfonylureas, or sulfonamide derivatives. It is also contraindicated in patients with Type 1 diabetes, diabetic ketoacidosis, and is not recommended for use during pregnancy or lactation.

Caution is advised and careful dose monitoring is necessary for patients who are at increased risk for hypoglycemia, such as the elderly and those with renal or hepatic impairment. Due to the risk of hypoglycemia, patients' ability to concentrate and react may be impaired, which is a factor to consider when operating machinery.

Overdose and Emergency Response

Overdose and When to Seek Help

The most significant and life-threatening outcome of Amarel (Glimepiride) overdose, whether intentional or accidental, is profound and persistent hypoglycemia (extremely low blood sugar). This physiological event affects the central nervous system, leading to manifestations collectively termed neuroglycopenic crisis.

Documented Overdose Manifestations

Symptoms and clinical signs formally listed in regulatory labeling include both autonomic and CNS effects, such as: anxiety, cold sweats, headache, nausea, extreme hunger, blurred vision, confusion, tremor, stupor, and speech disturbances. In severe cases, the overdose may progress rapidly to seizures or unconsciousness (coma). Severe hypoglycemia carries the official risk of permanent impairment of brain function.

When Immediate Medical Help Is Required

The regulatory standard mandates that immediate medical attention must be sought if any manifestation of severe hypoglycemia occurs. Contact emergency services immediately if the affected person collapses, experiences convulsions, or cannot be awakened. This critical response is necessary because the drug’s extended action can cause low blood sugar to recur even after initial correction.

Official Supportive Measures

The official management for severe hypoglycemia involves the administration of intravenous glucose (dextrose). Due to the sustained risk of recurrence, prolonged hospital observation is required, typically for 12 to 24 hours after treatment is discontinued, to ensure blood glucose concentrations remain stable.

Population-Specific Overdose Note

Regulatory documentation highlights that children (even after ingesting a small single tablet), elderly patients, and individuals with underlying renal or hepatic impairment are particularly susceptible to severe and prolonged hypoglycemia following overdose.

Therapeutic Uses of Amarel

What Amarel Treats: Main Uses and Benefits

Amarel (Glimepiride) is commonly used in adults for the management of Type 2 diabetes mellitus and is typically part of a treatment plan that includes appropriate diet and exercise. The primary therapeutic focus is managing the chronic condition of hyperglycemia (high blood sugar) and supporting the patient in situations where symptoms may intensify temporarily.

The medication is relevant for easing symptoms that interfere with daily functioning and is commonly used across conditions presenting with episodic manifestations, particularly when previous treatment efforts result in inadequate glycemic control. The condition categories for which it is relevant include: hyperglycemia, suboptimal treatment response, and symptom clusters related to systemic imbalance.

Quick Fact: Focus on Systemic Imbalance

Domain Focus Benefit
Primary Condition Type 2 Diabetes Mellitus Managing the physiological stress associated with chronic high blood sugar
Symptom Cluster Pronounced Hyperglycemia Helps ease the symptom load of thirst and frequent urination
Clinical Scenario Inadequate Glycemic Control Supports stability in conditions where symptoms may intensify temporarily

Regulatory References

  1. U.S. National Library of Medicine (DailyMed)

Eligibility and Restrictions for Use

The eligibility for Amarel (Glimepiride) is strictly defined by regulatory authorities for use in the approved patient population.

Populations Allowed

Amarel is formally indicated for adults (age 18 and older) diagnosed with Type 2 Diabetes Mellitus, as an adjunct to diet and exercise to improve glycemic control.

Populations Who Must Not Use Amarel (Contraindications)

Use is contraindicated in patients with:

  • Known hypersensitivity to glimepiride, other sulfonylureas, or sulfonamide derivatives.
  • Type 1 Diabetes Mellitus.
  • Diabetic Ketoacidosis (DKA).
  • Pregnancy or breastfeeding (lactation).
  • Severe renal or hepatic function disorders, as these conditions require a change to insulin therapy.

Eligibility Restrictions and Conditions

Population Category Official Regulatory Status
Pediatric Patients (Under 18) Not recommended; safety and efficacy are not established by regulatory bodies.
Older Adults Use requires caution in dose selection due to a heightened risk of low blood sugar and potential age-related kidney function changes.
G6PD Deficiency Caution should be used, and a non-sulfonylurea alternative should be considered, due to the risk of hemolytic anemia.

The drug is explicitly restricted from treating Type 1 diabetes and acute metabolic crises like DKA, as it is ineffective for these conditions according to regulatory labels.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Amarel (glimepiride) outlines several categories of interacting substances based on their potential to alter drug exposure or augment its therapeutic effect.

Interaction Type Interacting Substance/Class Official Regulatory Statement
Formal Restriction Oral Miconazole Severe hypoglycemia can occur with concomitant use.
Timing Requirement Colesevelam Glimepiride must be administered at least 4 hours prior to colesevelam due to reduced glimepiride absorption.
Pharmacokinetic CYP2C9 Inhibitors (e.g., Fluconazole) These agents may increase glimepiride plasma concentrations by affecting its metabolism.
Pharmacodynamic Other Antidiabetic Agents (e.g., Insulin, Metformin) Co-administration may result in a potentiation of the blood-glucose-lowering effect.
Population Note Elderly/Renally Impaired These groups have an increased risk for hypoglycemia when the medicine is used with other antidiabetic agents.

Substances that inhibit Glimepiride's CYP2C9 metabolism are documented to increase drug levels, while inducers, such as Rifampicin, are documented to decrease them. Furthermore, excessive alcohol consumption is noted to potentially potentiate or weaken the blood-glucose-lowering action of glimepiride in an unpredictable fashion. The overall interaction profile is defined by factors that either raise the drug's exposure in the body or enhance its effect on blood sugar.

Mechanism of Action

Blocking the K ATP Channel to Influence Insulin Release

Amarel exerts its primary action by targeting the Sulfonylurea Receptor 1 (SUR1) subunit of the ATP-sensitive potassium ( K ATP) channel on pancreatic beta cells. By acting as an inhibitor, the drug forces these channels to close, initiating the insulin secretagogue cascade that directly leads to an increased release of insulin into the bloodstream.

The Depolarization and Ca^2+ Signaling Cascade

The closure of the K ATP channels causes the beta cell membrane to depolarize. This change in electrical potential opens voltage-gated calcium channels, allowing a rapid influx of Ca^2+ ions. The resulting rise in intracellular calcium concentration triggers the exocytosis of insulin granules, which is the immediate mechanism for insulin release.

Extrapancreatic Effects on Glucose Regulation

Beyond the pancreas, Amarel's mechanism includes extrapancreatic effects that influence how tissues respond to insulin. This action influences the sensitivity of muscle and fat cells to circulating insulin, supporting increased cellular glucose uptake and resulting in a decrease in overall plasma glucose concentration.

Dosage and Administration Information

How to Use Amarel — Official Administration Instructions

Amarel (glimepiride) is an oral tablet for once-daily use. The official instructions for its administration must be followed exactly as prescribed by a healthcare provider.

Official Dosing and Timing

Administration Detail Official Requirement
Route of Administration Oral tablet.
Starting Dose Typically 1 mg or 2 mg once daily, with 1 mg recommended for elderly patients or those at higher risk.
Frequency and Timing Take once daily, either with breakfast or the first substantial meal of the day.
Dose Titration Doses may be increased in 1 mg or 2 mg increments, but no more frequently than every 1 to 2 weeks, based on blood glucose levels. The maximum recommended daily dose is 8 mg or 6 mg.

Procedural Rules

  • Tablet Handling: The tablets should be swallowed whole with some liquid. Note that some strengths are scored and can be divided into equal doses if required for precise dosing.
  • Missed Dose: If a dose is forgotten, the patient must not correct this by taking a higher dose later.
  • During Fasting/Illness: If the patient is not eating (e.g., due to illness or fasting), the dose must not be taken, as the drug is required to be taken with a substantial meal.
  • Concomitant Medication: If co-administering with Colesevelam, Amarel must be taken at least 4 hours prior to the Colesevelam dose.

Recent Clinical Evidence

Research evidence / Overview of studies for Amarel (Glimepiride)


Evidence for Use as Monotherapy in Type 2 Diabetes

The active substance was studied in research contexts that involved adults with Type 2 Diabetes Mellitus who were new to medication or had previously used minimal treatment. These research efforts primarily examined the use of the active substance alone (monotherapy). The core focus of these short-term studies was on outcomes related to systemic or functional imbalance, such as the measurements of key blood sugar biomarkers. Specifically, researchers monitored laboratory values like Glycated Hemoglobin (HbA1c) and Fasting Plasma Glucose (FPG).

Research monitored measurements during the study period, documenting patterns observed in the shifts of HbA1c and FPG from the start of the trials. The overall evidence base was derived from numerous studies for assessing the initial measurements of these surrogate markers in the adult population. However, results apply only to the populations studied, and the follow-up durations were typically short-term (generally spanning less than one year).


Evidence for Use in Combination Treatments

Studies also explored research scenarios where Amarel was introduced to adults with Type 2 Diabetes who had not achieved their glycemic goals while taking stable doses of metformin.

These Randomized Controlled Trials (RCTs) monitored whether a change in blood sugar control was measured when glimepiride was added to the existing regimen. The research examined how the HbA1c and FPG values evolved. Research documented the measurements taken, noting patterns in biomarker values when glimepiride was introduced as an adjunct. Findings were generally consistent for the measured short-term changes in glycemic control.


Long-Term Data and Follow-Up Studies

Whether long-term effects are measurable was evaluated in large, multi-year trials and observational cohort studies. These research efforts monitored outcomes reflecting daily functioning and activity level over defined time intervals. Researchers observed outcomes related to Major Adverse Cardiovascular Events (MACE), such as heart attack and stroke, and all-cause mortality.

The research describes the observed patterns of these cardiovascular events in the studied populations. Early trials were insufficient in duration to capture a meaningful number of clinical outcomes. This evidence contributes to the broader evidence landscape but certainty remains low for hard clinical endpoints compared to the extensive data available for short-term blood sugar markers.

Key Studies & References

  1. Comparison of the Efficacy of Glimepiride, Metformin, and Rosiglitazone Monotherapy in Korean Drug-Naïve Type 2 Diabetic Patients: The Practical Evidence of Antidiabetic Monotherapy Study

Frequently Asked Questions (FAQ)

Common questions about Amarel (FAQ)


Q: How long does it usually take to notice the effects of Amarel?

Official prescribing information indicates that the dose is typically adjusted based on blood glucose response, but no more frequently than every one to two weeks. This timeframe is consistent with the monitoring periods used to assess the glycemic response to the medication.


Q: Is it normal to feel tired when starting Amarel?

Dizziness is listed in official documents as a common adverse reaction that is not related to low blood sugar. However, generalized weakness or fatigue may be consistent with symptoms of hypoglycemia, which is a major safety risk addressed in the product information.


Q: Are there any specific foods or drinks I should avoid while using Amarel?

Excessive consumption of alcohol is noted to potentially increase or decrease the blood-glucose-lowering effect in an unpredictable way. Regarding administration, the official instructions specify that the tablet should be taken once daily with breakfast or the first substantial meal.


Q: Is Amarel safe for people with kidney problems?

Official documents state that use is contraindicated (not allowed) in patients with severe renal (kidney) function disorders. For individuals with kidney impairment, the regulatory information emphasizes the need for careful dose selection and monitoring by a healthcare professional due to the increased risk of low blood sugar.


Q: Is Amarel available as a generic medicine?

Amarel is the brand name for the active ingredient, glimepiride. Glimepiride is available as an oral tablet, which is the generic equivalent of Amarel.


Q: Are there different strengths or forms of Amarel?

The medication is formulated as an oral tablet. Official product information confirms that it is available in multiple strengths, which may include 1 mg, 2 mg, 3 mg, 4 mg, 6 mg, and 8 mg tablets.


Q: Can I drive or operate machinery while taking Amarel?

Due to the risk of hypoglycemia (low blood sugar), official warnings advise that a patient's ability to concentrate and react may be impaired. The regulatory information identifies this as a factor to be considered in situations that require attention, such as driving or operating machinery.


Q: What is the maximum duration of use described in clinical trials?

Research reviewed for regulatory purposes included short-term studies focused on blood sugar markers that lasted less than one year. However, the drug's long-term safety, including Major Adverse Cardiovascular Events, was monitored in multi-year trials.


Q: What is the recommended approach if I develop a rash while taking Amarel?

If a severe hypersensitivity reaction, such as Stevens-Johnson Syndrome—which may involve a rash—is suspected, the prescribing information directs that the medication must be discontinued immediately. Any unusual skin reaction is a factor that is important to review with a healthcare professional.


Q: Is Amarel considered a first-line medication?

Official documentation indicates that Glimepiride is approved as an adjunct to diet and exercise for adults with Type 2 Diabetes. This means its primary role is to improve blood sugar control alongside lifestyle management.


Q: Can Amarel affect my sleep?

Nightmares are reported as a symptom that may be associated with hypoglycemia (low blood sugar). Since low blood sugar is the most prominent safety risk of the medication, it is important to be aware of all associated signs.


Q: Does Amarel interact with common pain relievers like ibuprofen?

Official prescribing information indicates that caution is necessary with certain pain relievers. Both salicylates (like aspirin) and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) may potentiate (increase) the medication's blood-glucose-lowering effect.


Q: Can I take herbal supplements while I am taking Amarel?

Glimepiride may interact with certain herbal dietary supplements. The potential for interactions means that all supplements, including herbal ones, are subjects for review with a healthcare provider.


Q: Will Amarel interfere with my birth control pills?

Regulatory documents state that glimepiride may interact with estrogen or progestin hormones, such as those found in birth control pills. This potential interaction may require closer monitoring by a healthcare provider.


Q: Do I need special monitoring or blood tests while on Amarel?

Routine monitoring is recommended, including regular checks of blood and urine glucose levels, and glycosylated hemoglobin ( HbA1c). Additionally, regular monitoring of liver function and blood cell counts may be required.


Q: Can Amarel cause mood changes or anxiety?

Anxiety is reported as a symptom that may be associated with hypoglycemia (low blood sugar). This symptom is reported in the context of hypoglycemia, which is the medication's most prominent safety risk.


Q: Why do official documents emphasize a certain restriction on Amarel use?

Restrictions and contraindications are established based on the potential for harm or lack of effectiveness. For example, the medication is contraindicated in Type 1 Diabetes Mellitus because it is ineffective for that condition.


Q: Does Amarel have a 'Black Box Warning' or similar safety classification?

Glimepiride does not carry an FDA Boxed Warning (often called a Black Box Warning). However, official documentation does include a warning regarding the potential increased risk of cardiovascular mortality associated with sulfonylureas.


Q: Does Amarel make existing medical conditions worse?

Official information advises caution or contraindicates use in patients with certain pre-existing conditions. For example, it is restricted for patients with G6PD deficiency due to the risk of hemolytic anemia, and caution is needed for severe kidney or liver impairment.


Q: Does Amarel interact with vitamins or mineral supplements?

Specific vitamins or minerals, such as chromium, and certain herbal supplements may interact with the medication. The use of all supplements is a topic that requires review with a healthcare provider.


Q: Is Amarel a controlled substance?

Official regulatory information, such as that provided by the U.S. Drug Enforcement Administration (DEA), does not list glimepiride as a controlled substance.


Q: Does Amarel interact with anesthetic medications used in surgery?

Official warnings note that blood sugar can be affected by surgery or stress. Medication management during the perioperative period (around the time of surgery) is a topic for discussion with the surgical team.


Q: How does the effectiveness of Amarel change over time?

Regulatory documents indicate that as blood sugar control improves, the required dose of Glimepiride may decrease due to enhanced insulin sensitivity. This change requires monitoring by a healthcare professional to ensure appropriate dose levels are maintained.


Q: Can Amarel affect fertility in men or women?

The regulatory prescribing information does not specifically address effects on human fertility for either men or women.

How should Amarel be stored and disposed of?

How to Store and Dispose of Amarel (Glimepiride)

Glimepiride tablets must be stored at Controlled Room Temperature, which is officially defined as 20 C to 25 C (68 F to 77 F). The product must be strictly protected from heat, moisture, and direct light, and must not be frozen.

Handling and Child Safety

To maintain stability, the tablets must be stored in a closed container. It is mandatory to keep Amarel out of the reach of children.

Disposal Requirements

Official labeling requires that users do not keep outdated medicine or medicine that is no longer needed. Unused medicine should be disposed of by consulting a healthcare professional for guidance. Disposal in household trash must follow official regulatory guidance, such as mixing the product with an unappealing substance before discarding it.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Amarel found in:

A-Z Index: